Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Retained Earnings (2016 - 2025)

Iradimed (IRMD) has disclosed Retained Earnings for 13 consecutive years, with $66.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 23.9% to $66.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $66.3 million, a 23.9% increase, with the full-year FY2024 number at $56.8 million, up 31.28% from a year prior.
  • Retained Earnings was $66.3 million for Q3 2025 at Iradimed, up from $62.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $66.3 million in Q3 2025 to a low of $6127.0 in Q1 2022.
  • A 5-year average of $36.1 million and a median of $43.4 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 80.98% in 2022, then soared 611087.2% in 2023.
  • Iradimed's Retained Earnings stood at $17012.0 in 2021, then surged by 277729.07% to $47.3 million in 2022, then decreased by 8.48% to $43.3 million in 2023, then skyrocketed by 31.28% to $56.8 million in 2024, then grew by 16.82% to $66.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Retained Earnings are $66.3 million (Q3 2025), $62.9 million (Q2 2025), and $59.3 million (Q1 2025).